Spironolactone Tablet, Film Coated
Product Images NDC 42708-101

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 42708-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

42708-101-30 Spironolactone Tablet Usp 25mg X 30 (25mglabel)

Label for Spironolactone Tablet USP, 25 mg oral film-coated tablets, containing 30 tablets. The label includes storage instructions to store at controlled room temperature and warnings to keep the container tightly closed and out of reach of children. It is distributed by QPharma, Inc., Cedar Knolls, NJ, and marked Rx Only. The label indicates this is a sample not for sale with dosage directions to be seen in the package insert.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of spironolactone, the active ingredient in the product Spironolactone 25 mg film-coated tablets by QPharma, Inc. The structure shows its steroid backbone with attached functional groups as illustrated in the molecular formula.*

FDA Label Image

Figure01 (Fig01)

A Kaplan-Meier survival curve comparing the probability over time (months) between a Spironolactone group (n=822) and a Placebo group (n=841). The graph shows higher survival probability for the Spironolactone group compared to Placebo over 36 months, with a log-rank p-value less than 0.001 indicating statistical significance.*

FDA Label Image

Figure02 (Fig02)

A forest plot showing hazard ratios (HR) with 95% confidence intervals (CI) for various subgroups related to spironolactone treatment versus placebo. Subgroups include age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA class, diabetes, serum creatinine, creatinine clearance, potassium levels, digoxin, ACE inhibitor use, and beta blocker use. The plot compares the effectiveness of spironolactone against placebo across these groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.